Maryland Heights, MO, February 14, 2017 --(PR.com
)-- The global dilated cardiomyopathy therapeutics market is estimated to reach USD 300 Million in 2020, declining at a CAGR of 6.0% from 2016 to 2020, due to significant increase in drug side effects and medical devices substitution worldwide.
Browse Dilated Cardiomyopathy Therapeutics Market by Drug Classes (Aldosterone Antagonists, Angiotensin II Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, and Beta-Blockers) and Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs 2016-2020 at https://www.ihealthcareanalyst.com/report/dilated-cardiomyopathy-therapeutics-market/
Dilated cardiomyopathy (DCM) is also referred to as alcoholic cardiomyopathy, congestive, ischemic, primary cardiomyopathy, idiopathic, and peripartum cardiomyopathy. It is characterized by the enlargement of ventricular chamber along with systolic dysfunction. Dilated cardiomyopathy is the most common form of non-ischemic cardiomyopathy condition that involves decreased heart function due to an enlarged heart which cannot pump blood efficiently and can affect the lungs, liver, and other body systems. Dilated cardiomyopathy can develop at any age but it is more common among people aged between 20 years and 60 years. Standard therapy may include salt restriction, ACE inhibitors, diuretics, and digitalis and anticoagulants may also be used.
The global dilated cardiomyopathy therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes (aldosterone antagonists, angiotensin ii receptor blockers, angiotensin-converting enzyme inhibitors, and beta-blockers) and clinical pipeline analysis of phase 1, 2 and 3 drugs, and forecasts growth trends (CAGR% - 2016 to 2020). The global dilated cardiomyopathy therapeutics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global dilated cardiomyopathy therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global dilated cardiomyopathy therapeutics market and included in this report are Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, and Vericel Corporation.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/dilated-cardiomyopathy-therapeutics-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043